Browse by UCL people
Group by: Type | Date
Number of items: 15.
2021
Turkova, A;
White, E;
Mujuru, HA;
Kekitiinwa, AR;
Kityo, CM;
Violari, A;
Lugemwa, A;
... ODYSSEY Trial Team; + view all
(2021)
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
The New England Journal of Medicine
, 385
(27)
pp. 2531-2543.
10.1056/NEJMoa2108793.
|
2020
|
Desai, M;
White, E;
Vora, N;
Gilson, R;
Lacey, C;
Gafos, M;
Clarke, A;
... Dunn, DT; + view all
(2020)
High incidence of Hepatitis C virus infection observed in the PROUD study of HIV pre‐exposure prophylaxis.
Journal of Viral Hepatitis
, 27
(8)
pp. 852-857.
10.1111/jvh.13297.
|
2019
|
Miltz, A;
Lampe, F;
McCormack, S;
Dunn, D;
White, E;
Rodger, A;
Phillips, A;
... Gafos, M; + view all
(2019)
Prevalence and correlates of depressive symptoms among gay, bisexual and other men who have sex with men in the PROUD randomised clinical trial of HIV pre-exposure prophylaxis.
BMJ Open
, 9
(12)
, Article e031085. 10.1136/bmjopen-2019-031085.
|
 |
|
Miltz, AR;
Lampe, FC;
Bacchus, LJ;
McCormack, S;
Dunn, D;
White, E;
Rodger, A;
... Gafos, M; + view all
(2019)
Intimate partner violence, depression, and sexual behaviour among gay, bisexual and other men who have sex with men in the PROUD trial.
BMC Public Health
, 19
, Article 431. 10.1186/s12889-019-6757-6.
|
|
|
O'Halloran, C;
Rice, B;
White, E;
Desai, M;
T Dunn, D;
McCormack, S;
Sullivan, AK;
... Gafos, M; + view all
(2019)
Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants.
International Journal of Drug Policy
, 74
pp. 246-254.
10.1016/j.drugpo.2019.10.007.
|
|
|
White, E;
Dunn, DT;
Desai, M;
Gafos, M;
Kirwan, P;
Sullivan, AK;
Clarke, A;
... PROUD study group; + view all
(2019)
Predictive factors for HIV infection among men who have sex with men and who are seeking PrEP: a secondary analysis of the PROUD trial.
Sexually Transmitted Infections
, 95
(6)
pp. 449-454.
10.1136/sextrans-2018-053808.
|
|
2018
|
Gafos, M;
Horne, R;
Nutland, W;
Bell, G;
Rae, C;
Wayal, S;
Rayment, M;
... McCormack, S; + view all
(2018)
The Context of Sexual Risk Behaviour Among Men Who Have Sex with Men Seeking PrEP, and the Impact of PrEP on Sexual Behaviour.
AIDS and Behavior
10.1007/s10461-018-2300-5.
(In press).
|
|
|
Geretti, AM;
White, E;
Orkin, C;
Tostevin, A;
Tilston, P;
Chadwick, D;
Leen, C;
... UK HIV Drug Resistance Database and UK CHIC Study, .; + view all
(2018)
Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance.
Journal of Antimicrobial Chemotherapy
, Article dky468. 10.1093/jac/dky468.
(In press).
|
|
2017
|
Gafos, M;
Brodnicki, E;
Desai, M;
McCormack, S;
Nutland, W;
Wayal, S;
White, E;
... PROUD Study Team; + view all
(2017)
Acceptability of an open-label wait-listed trial design: Experiences from the PROUD PrEP study.
PLoS One
, 12
(4)
, Article e0175596. 10.1371/journal.pone.0175596.
|
|
|
Smit, E;
White, E;
Clark, D;
Churchill, D;
Zhang, H;
Collins, S;
Pillay, D;
... UK HIV Drug Resistance Database and the UK Collaborative HIV Coh, .; + view all
(2017)
An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs.
Journal of Antimicrobial Chemotherapy
10.1093/jac/dkx091.
|
|
2016
|
Dunn, DT;
Gafos, M;
White, E;
McCormack, S;
(2016)
HIV moments and pre-exposure prophylaxis - Authors' reply.
Lancet
, 387
(10027)
p. 1508.
10.1016/S0140-6736(16)00695-4.
|
|
El Bouzidi, K;
White, E;
Mbisa, JL;
Sabin, CA;
Phillips, AN;
Mackie, N;
Pozniak, AL;
... UK HIV Drug Resistance Database (UKHDRD) and the UK Collaborativ; + view all
(2016)
HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK.
Journal of Antimicrobial Chemotherapy
, 71
(12)
pp. 3487-3494.
10.1093/jac/dkw343.
|
|
|
Lambert-Niclot, S;
George, EC;
Pozniak, A;
White, E;
Schwimmer, C;
Jessen, H;
Johnson, M;
... NEAT 001/ANRS 143 Study Group, .; + view all
(2016)
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
Journal of Antimicrobial Chemotherapy
, 71
(4)
pp. 1056-1062.
10.1093/jac/dkv427.
|
|
Tostevin, ATL;
Dunn, DT;
White, EM;
Sabin, C;
Pillay, D;
Williams, I;
(2016)
Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom.
HIV Medicine
, 18
(3)
pp. 204-213.
10.1111/hiv.12414.
|
|
White, EM;
Tostevin, A;
Sabin, C;
Pillay, D;
Dunn, DT;
Smit, E;
Churchill, D;
... Booth, C; + view all
(2016)
No evidence that HIV-1 subtype C infection compromises the efficacy of tenofovir containing regimens: cohort study in the United Kingdom.
Journal of Infectious Diseases
, 214
(9)
pp. 1302-1308.
10.1093/infdis/jiw213.
|
